Therapy for treatment-refractory chronic hepatitis C virus genotype 1b infection: A retrospective analysis.

[1]  L. Sidiropoulos,et al.  The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha‐2b plus ribavirin treatment of naïve and nonresponder chronic hepatitis C patients , 2005, Journal of viral hepatitis.

[2]  Z. Abbas,et al.  Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin. , 2004, JPMA. The Journal of the Pakistan Medical Association.

[3]  E. Schiff,et al.  Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. , 2004, Gastroenterology.

[4]  William M. Lee,et al.  Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. , 2004, Gastroenterology.

[5]  H. Nomura,et al.  Pilot study of prolonged interferon-alpha retreatment in chronic hepatitis C patients with genotype 1b. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[6]  M. Manns,et al.  Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.

[7]  C. Datz,et al.  Impact of high‐dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy , 2003, Liver international : official journal of the International Association for the Study of the Liver.

[8]  G. Gerken,et al.  Interleukin‐2 has no additional therapeutic efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon‐α plus ribavirin , 2003, European journal of clinical investigation.

[9]  R. Carithers,et al.  A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy , 2003, Hepatology.

[10]  P. Marcellin,et al.  Reinforced interferon alpha‐2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial , 2003, Journal of viral hepatitis.

[11]  L. Adinolfi,et al.  Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial , 2003, Gut.

[12]  Kirk A Easley,et al.  Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C. , 2003 .

[13]  M. Dijkgraaf,et al.  Chronic hepatitis C patients with a post‐treatment virological relapse re‐treated with an induction dose of 18 MU interferon‐α in combination with ribavirin and amantadine: a two‐arm randomized pilot study , 2003, Journal of viral hepatitis.

[14]  Yoshiyuki Suzuki,et al.  Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[15]  K. Tolman,et al.  Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy , 2003 .

[16]  E. Schiff,et al.  Epoetin alfa treatment of anemic HCV-infected patients allows for maintenance of ribavirin dose, increases hemoglobin levels, and improves quality of life Vs placebo: A randomized, double-blind, multicenter study , 2003 .

[17]  William M. Lee,et al.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.

[18]  H. Klinker,et al.  Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin. , 2002, European journal of medical research.

[19]  E. Bini,et al.  Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to inferferon monotherapy or combination therapy, and in combination therapy relapsers , 2001 .

[20]  Z. Younossi,et al.  Triple Combination of Interferon Alpha‐2b, Ribavirin, and Amantadine for Treatment of Chronic Hepatitis C , 2000, Journal of clinical gastroenterology.

[21]  A. Craxì,et al.  Chronic hepatitis C: retreatment of relapsers. An evidence-based approach. , 2000, Seminars in gastrointestinal disease.

[22]  P. Kwo.  Treatment of chronic hepatitis C in nonresponders to interferon monotherapy , 2000, Current gastroenterology reports.

[23]  S. James,et al.  Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon , 1999 .

[24]  F. Caroli-Bosc,et al.  Second Generation of the Automated Cobas Amplicor HCV Assay Improves Sensitivity of Hepatitis C Virus RNA Detection and Yields Results That Are More Clinically Relevant , 1999, Journal of Clinical Microbiology.

[25]  M A Torkington,et al.  An evidence-based approach , 1998, British Dental Journal.

[26]  G. Colucci,et al.  Multicenter Evaluation of the COBAS AMPLICOR HCV Assay, an Integrated PCR System for Rapid Detection of Hepatitis C Virus RNA in the Diagnostic Laboratory , 1998, Journal of Clinical Microbiology.

[27]  M. Poljak,et al.  Evaluation of the automated COBAS AMPLICOR hepatitis C virus PCR system , 1997, Journal of clinical microbiology.

[28]  Eugene R. Schiff,et al.  National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C , 1997, Hepatology.

[29]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[30]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[31]  G. Plosker,et al.  Interferon Alfacon-1 , 2012, Drugs.

[32]  E. Keeffe,et al.  Retreatment of chronic hepatitis C virus infection. , 2004, Reviews in gastroenterological disorders.

[33]  Y. Jeong,et al.  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .

[34]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .